The TGA and Arrow Pharma have issued a product defect alert for a batch of Valpam 5 for potentially containing lower strength tablets
The alert is due to the possibility that the blister strip, containing yellow Valpam 5 tablets, could include white Valpam 2mg tablets.
The affected batch is numbered CP218 and contains Valpam 5mg tablet blister packs (50 tablets) with an expiry date of January 2021.
The alert follows one instance where a blister pack of Valpam 5mg was found to contain a single Valpam 2mg tablet in place of one of the 5mg tablets.
No other batches are known to be affected, say the TGA and Arrow.
Arrow Pharma has advised both consumers and health professionals to make a visual inspection of blisters from batch CP218 before using or dispensing them, to ensure that all the tablets are a light yellow colour.
“The correct tablets should be marked with ‘DZ 5’ on one side, however this marking will only be visible on tablets that are loaded into the packaging with the numbered side facing the clear plastic blister,” Arrow advises.
“If a blister is found to contain a white or off-white tablet alongside the other yellow tablets, these blisters are affected and should not be used or supplied.
“If no anomalies are found the product may continue to be supplied and used as normal and no further action is necessary.”
Health professionals as well as consumers can also choose to visually inspect Valpam 5 blister packs from other batches, it says, though only one batch is currently known to be affected.
Consumers have been encouraged to return any affected blisters unopened to the place of purchase for refund or replacement.